53 resultados para star : Bd 28 4211
Resumo:
A 47 ans, Edwige Feuillère est la vedette principale du Blé en herbe (1954), où elle incarne une femme d'âge mûr qui entreprend l'initiation amoureuse d'un jeune homme ; quatre ans plus tard, elle joue dans En cas de malheur le rôle d'une épouse qui, dans l'abnégation la plus complète, accepte les infidélités de son mari et s'efface devant le couple formé par Jean Gabin (54 ans) et Brigitte Bardot (24 ans). La place accordée aux deux personnages interprétés par Feuillère sera examinée en termes de construction de l'image d'une star vieillissante à travers l'étude du triangle amoureux qui structure le récit de ces deux adaptations (qu'il s'agira de comparer aux romans de Colette et de Simenon dont elles sont issues), de la stratégie promotionnelle pratiquée et des discours émis à propos de Feuillère au sein de la réception critique. Le contexte de production des films ainsi que certaines versions non retenues du scénario seront discutées à partir des archives du fonds Claude Autant-Lara de la Cinémathèque suisse.
Resumo:
BACKGROUND: Fever is a frequent cause of medical consultation among returning travelers. The objectives of this study were to assess whether physicians were able to identify patients with influenza and whether the use of an influenza rapid diagnostic test (iRDT) modified the clinical management of such patients. METHODS: Randomized controlled trial conducted at 2 different Swiss hospitals between December 2008 and November 2012. Inclusion criteria were 1) age ≥18 years, 2) documented fever of ≥38 °C or anamnestic fever + cough or sore throat within the last 4 days, 3) illness occurring within 14 days after returning from a trip abroad, 4) no definitive alternative diagnosis. Physicians were asked to estimate the likelihood of influenza on clinical grounds, and a single nasopharyngeal swab was taken. Thereafter patients were randomized into 2 groups: i) patients with iRDT (BD Directigen A + B) performed on the nasopharyngeal swab, ii) patients receiving usual care. A quantitative PCR to detect influenza was done on all nasopharyngeal swabs after the recruitment period. Clinical management was evaluated on the basis of cost of medical care, number of X-rays requested and prescription of anti-infective drugs. RESULTS: 100 eligible patients were referred to the investigators. 93 patients had a naso-pharyngeal swab for a PCR and 28 (30%) swabs were positive for influenza. The median probability of influenza estimated by the physician was 70% for the PCR positive cases and 30% for the PCR negative cases (p < 0.001). The sensitivity of the iRDT was only 20%, and specificity 100%. Mean medical cost for the patients managed with iRDT and without iRDT were USD 581 (95%CI 454-707) and USD 661 (95%CI 522-800) respectively. 14/60 (23%) of the patients managed with iRDT were prescribed antibiotics versus 13/33 (39%) in the control group (p = 0.15). No patient received antiviral treatment. CONCLUSION: Influenza was a frequent cause of fever among these febrile returning travelers. Based on their clinical assessment, physicians had a higher level of suspicion for influenza in PCR positive cases. The iRDT used in this study showed a disappointingly low sensitivity and can therefore not be recommended for the management of these patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT00821626.
Resumo:
BACKGROUND: Rivaroxaban has become an alternative to vitamin-K antagonists (VKA) for stroke prevention in non-valvular atrial fibrillation (AF) patients due to its favourable risk-benefit profile in the restrictive setting of a large randomized trial. However in the primary care setting, physician's motivation to begin with rivaroxaban, treatment satisfaction and the clinical event rate after the initiation of rivaroxaban are not known. METHODS: Prospective data collection by 115 primary care physicians in Switzerland on consecutive nonvalvular AF patients with newly established rivaroxaban anticoagulation with 3-month follow-up. RESULTS: We enrolled 537 patients (73±11years, 57% men) with mean CHADS2 and HAS-BLED-scores of 2.2±1.3 and 2.4±1.1, respectively: 301(56%) were switched from VKA to rivaroxaban (STR-group) and 236(44%) were VKA-naïve (VN-group). Absence of routine coagulation monitoring (68%) and fixed-dose once-daily treatment (58%) were the most frequent criteria for physicians to initiate rivaroxaban. In the STR-group, patient's satisfaction increased from 3.6±1.4 under VKA to 5.5±0.8 points (P<0.001), and overall physician satisfaction from 3.9±1.3 to 5.4±0.9 points (P<0.001) at 3months of rivaroxaban therapy (score from 1 to 6 with higher scores indicating greater satisfaction). In the VN-group, both patient's (5.4±0.9) and physician's satisfaction (5.5±0.7) at follow-up were comparable to the STR-group. During follow-up, 1(0.19%; 95%CI, 0.01-1.03%) ischemic stroke, 2(0.37%; 95%CI, 0.05-1.34%) major non-fatal bleeding and 11(2.05%; 95%CI, 1.03-3.64%) minor bleeding complications occurred. Rivaroxaban was stopped in 30(5.6%) patients, with side effects being the most frequent reason. CONCLUSION: Initiation of rivaroxaban for patients with nonvalvular AF by primary care physicians was associated with a low clinical event rate and with high overall patient's and physician's satisfaction.
Resumo:
Cet ouvrage réunit des spécialistes de l'étude de la bande dessinée qui proposent une série d'éclairages sur la manière dont les productions culturelles européennes ont diffusé, exploité, reformulé ou détourné l'imaginaire et le langage des comics venus d'outre-Atlantique. L'approche se veut résolument comparative, interculturelle et intermédiale : les chercheurs abordent autant Edgar P. Jacobs ou les récents albums de Serge Lehman que les séries TV de science-fiction britanniques ou les films d'Alain Resnais, et se proposent d'interroger la réception et les réappropriations de motifs et genres populaires situés au croisement d'influences et de références diverses. La production américaine est ainsi discutée dans toute sa richesse, des super-héros à l'underground, à travers des (re)lectures proposées en Europe.